Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1996
Business Overview: The Company is a developer and manufacturer of specialty medical devices. The reporting period was characterized by aggressive expansion through strategic acquisitions, including the merger with EP Technologies, Inc. (EPT), and the cash acquisitions of Symbiosis Corporation and Endotech/MinTec Inc.
Key Financial Metrics
| Metric (in thousands) | Q2 1996 | Q2 1995 | 6 Months 1996 | 6 Months 1995 |
|---|---|---|---|---|
| Net Sales | $357,188 | $277,952 | $679,571 | $540,861 |
| Gross Profit | $262,304 | $195,875 | $499,053 | $380,002 |
| Gross Margin % | 73.4% | 70.5% | 73.4% | 70.3% |
| Operating Income | $51,622 | $74,552 | $86,021 | $23,771 |
| Net Income (Loss) | $23,510 | $49,029 | $22,519 | ($15,033) |
| Diluted EPS | $0.12 | $0.27 | $0.12 | ($0.09) |
| Cash & Equivalents (End of Period) | $52,698 | $199,995 | $52,698 | $199,995 |
| Commercial Paper Outstanding | $235,000 | $0 | $235,000 | $0 |
| Working Capital | $118,000 | $283,000 | $118,000 | $283,000 |
Note: Working capital calculated as Total Current Assets ($583,326) minus Total Current Liabilities ($465,336) for June 30, 1996, and Total Current Assets ($556,645) minus Total Current Liabilities ($273,677) for Dec 31, 1995.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 28.5% in Q2 1996 and 25.6% for the six-month period compared to 1995. International revenues grew 48.4% in Q2, though negatively impacted by $8.4 million in foreign currency fluctuations.
- Profitability Impact: Reported net income decreased significantly in Q2 1996 ($23.5M vs $49.0M) due to special charges. However, excluding special charges, net income increased 44.3% to $70.7 million.
- Special Charges: The Company recorded $128.3 million in special charges for the six months ended June 30, 1996 ($113.7 million net-of-tax). These relate to the EPT merger and acquisitions of Symbiosis and Endotech/MinTec, including $96.0 million for purchased R&D and integration costs.
- Liquidity Shift: Cash and marketable securities declined from $161.2 million (Dec 31, 1995) to $78.1 million (June 30, 1996). This reduction was driven by $225.1 million in acquisition payments, capital expenditures, and stock repurchases, partially offset by the issuance of $235 million in commercial paper.
- Debt Structure: The Company replaced a $121 million credit line with a new $350 million revolving credit facility and initiated a commercial paper program, resulting in $235 million outstanding at quarter-end.
Guidance, Outlook, and Risks
- Integration Outlook: Management expects integration of acquired businesses to be substantially completed by the end of 1997. Estimated remaining cash outflows for integration are $45.1 million for the remainder of 1996 and $19.2 million thereafter.
- Strategic Focus: The Company plans to continue aggressive investment in international organizations, global systems, and manufacturing capacity. Management believes cash flows and borrowing capacity are sufficient to meet needs through the end of 1996.
- Legal Contingencies: The Company faces numerous patent infringement lawsuits (e.g., Schneider, SCIMED, ACS, Target Therapeutics, C.R. Bard, Cook Inc., Cordis). A preliminary injunction against SCIMED's Venture microcatheters was granted but stayed pending appeal. Management asserts meritorious defenses but acknowledges adverse outcomes could materially affect operations.
- Market Risks: Continued consolidation in U.S. healthcare and managed care trends may pressure selling prices and gross margins. International expansion exposes the Company to currency fluctuation risks.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating Symbiosis, Endotech/MinTec, and EPT, and whether integration costs remain within the estimated $45.1 million for the remainder of 1996.
- Legal Exposure: Monitor the status of the preliminary injunction against SCIMED's Venture microcatheters and the outcomes of pending patent arbitrations scheduled for October 1996.
- Liquidity Management: Confirm the Company's ability to service the $235 million commercial paper obligation and maintain the required financial covenants under the new $350 million credit agreement.
- Margin Sustainability: Assess whether the 73.4% gross margin is sustainable given the noted pressures from healthcare cost containment and competition.
- Stock Repurchase Program: Track the execution of the authorized 15 million share repurchase program and the impact of the contingent stock repurchase obligation ($24.9 million).